unknown
Stage
2
Investors
About
Immusoft engineers patient-derived B cells to become therapeutic protein-producing plasma cells, which are infused back into patients to provide durable and personalized protein therapies.
Explore Immusoft's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.